Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 13/20 | 0.53 |
| ▸ | NPY1R | P25929 | 7/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laminin SCHEMBL2182807 | 1.00 | OPRD1 (0.55) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29479578 | 0.94 | OPRM1 (0.53) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL30211355 | 0.93 | NPY4R (0.52) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29502186 | 0.92 | NPY4R (0.52) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL30405659 | 0.90 | NPY4R (0.53) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL31307267 | 0.90 | OPRM1 (0.56) | OPRD1OPRM1OPRK1KISS1R | |
| SCHEMBL30104120 | 0.89 | OPRM1 (0.45) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29472190 | 0.89 | OPRD1 (0.54) | OPRD1OPRM1OPRK1KISS1R | |
| SCHEMBL30211356 | 0.88 | NPY4R (0.50) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| Laminin SCHEMBL29354054 | 0.88 | NTSR1 (0.56) | OPRD1OPRM1OPRK1NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107522773-B | Pentapeptide modified rhodamine B compound and preparation method and application thereof | 武汉工程大学 | 2021-06-01 | — | — | CN | claimed |
| CN-107739528-A | A kind of pentapeptide is modified cyanine dye compound and its preparation method and application | 武汉工程大学 | 2018-02-27 | — | — | CN | claimed |
| CN-107522773-A | A kind of pentapeptide is modified rhodamine B compound and its preparation method and application | 武汉工程大学 | 2017-12-29 | — | — | CN | claimed |
| CN-103435684-B | 18f-fluorine mark pentapeptide title complex and synthetic method | WUHAN INSTITUTE OF TECHNOLOGY (CN) | 2015-10-28 | — | — | CN | claimed |
| CN-103435684-A | 18F-fluorine labeling pentapeptide complex and synthetic method thereof | WUHAN INST TECHNOLOGY | 2013-12-11 | — | — | CN | claimed |
| CN-107522773-B | Pentapeptide modified rhodamine B compound and preparation method and application thereof | 武汉工程大学 | 2021-06-01 | — | — | CN | disclosed |
| CN-112494664-A | Polysaccharide magnetic resonance and fluorescence dual-mode imaging diagnostic agent, preparation method thereof and diagnostic agent | 武汉工程大学 | 2021-03-16 | — | — | CN | disclosed |
| CN-112494664-A | Polysaccharide magnetic resonance and fluorescence dual-mode imaging diagnostic agent, preparation method thereof and diagnostic agent | 武汉工程大学 | 2021-03-16 | — | — | CN | disclosed |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| CN-107739528-A | A kind of pentapeptide is modified cyanine dye compound and its preparation method and application | 武汉工程大学 | 2018-02-27 | — | — | CN | disclosed |
| CN-107522773-A | A kind of pentapeptide is modified rhodamine B compound and its preparation method and application | 武汉工程大学 | 2017-12-29 | — | — | CN | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| CN-103435684-A | 18F-fluorine labeling pentapeptide complex and synthetic method thereof | WUHAN INST TECHNOLOGY | 2013-12-11 | — | — | CN | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
| CN-1694717-A | Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation | OMEROS CORP (US) | 2005-11-09 | — | — | CN | disclosed |
| US-20030195461-A1 | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation | OMEROS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-6492332-B1 | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation | OMEROS CORPORATION | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRD1 3859/4885OPRM1 3352/4885OPRK1 3229/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885OPRM1 2317/4885OPRK1 2737/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885OPRM1 2317/4885OPRK1 2737/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | OPRD1 2871/4885OPRM1 1535/4885OPRK1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.